Data gathered: January 22
AI Stock Analysis - Astrazeneca (AZN)
Analysis generated November 27, 2024. Powered by Chat GPT.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company operates in various therapeutic areas, including oncology, cardiovascular, renal & metabolism, respiratory, and immunology. AstraZeneca has a strong presence in over 100 countries, and its innovative medicines are used by millions of patients worldwide.
Stock Alerts - Astrazeneca (AZN)
 |
Astrazeneca | January 16 News Alert: AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights – AZN |
|
Astrazeneca | January 9 News Alert: ASTRAZENECA SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZN |
|
Astrazeneca | November 5 Price is down by -7% in the last 24h. |
|
Astrazeneca | October 30 Price is down by -5.2% in the last 24h. |
Alternative Data for Astrazeneca
About Astrazeneca
AstraZeneca PLC belongs to the healthcare sector. The company develops and markets pharmaceutical products for various therapeutic classes such as gastrointestinal, cardiovascular, respiratory, cancer, immunology, and neuroscience.
| Price | $68.20 |
| Target Price | Sign up |
| Volume | 2,720,000 |
| Market Cap | $208B |
| Year Range | $63.2 - $87.62 |
| Dividend Yield | 2.23% |
| PE Ratio | 32.02 |
| Analyst Rating | 100% buy |
| Earnings Date | February 6 '25 |
| Industry | Drug Manufacturers |
In the news
 |
Arkadios Wealth Advisors Sells 3,786 Shares of AstraZeneca PLC (NASDAQ:AZN)January 22 - ETF Daily News |
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZNJanuary 21 - GlobeNewswire |
|
The Gross Law Firm Notifies Shareholders of AstraZeneca PLC (AZN) of a Class Action Lawsuit and an Upcoming DeadlineJanuary 21 - GlobeNewswire |
|
 |
Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZNJanuary 21 - Investing.com |
|
AstraZeneca PLC (NASDAQ:AZN) Receives Average Rating of “Buy” from BrokeragesJanuary 20 - ETF Daily News |
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens BermanJanuary 20 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 13.6B | 3.08B | 10.5B | 1.43B | 4.1B | 0.457 |
| Q2 '24 | 12.9B | 2.18B | 10.8B | 1.93B | 4.12B | 0.990 |
| Q1 '24 | 12.7B | 2.22B | 10.5B | 2.18B | 4.57B | 1.030 |
| Q4 '23 | 12B | 2.31B | 9.72B | 960M | 2.18B | 0.730 |
| Q3 '23 | 11.5B | 2.1B | 9.4B | 1.37B | 3.33B | 0.870 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$143.05 3.4% | 43 |
 |
Eli Lilly and CompanyLLY |
$755.78 1.8% | 63 |
 |
PfizerPFE |
$26.34 1.1% | 38 |
 |
AbbVieABBV |
$168.52 2.4% | 53 |
 |
TherapeuticsMDTXMD |
$1.06 1% | 37 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Rohit Khanna Democrat |
Nov 8, 23 | Buy | $1K - $15K |
| Michael McCaul Republican |
Sep 20, 23 | Sell | $100K - $250K |
| Michael McCaul Republican |
Sep 20, 23 | Sell | $50K - $100K |
Read more about Astrazeneca (AZN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Astrazeneca?
The Market Cap of Astrazeneca is $208B.
What is Astrazeneca's PE Ratio?
As of today, Astrazeneca's PE (Price to Earnings) ratio is 32.02.
When does Astrazeneca report earnings?
Astrazeneca will report its next earnings on February 6 '25.
What is the current stock price of Astrazeneca?
Currently, the price of one share of Astrazeneca stock is $68.20.
How can I analyze the AZN stock price chart for investment decisions?
The AZN stock price chart above provides a comprehensive visual representation of Astrazeneca's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Astrazeneca shares. Our platform offers an up-to-date AZN stock price chart, along with technical data analysis and alternative data insights.
Does AZN offer dividends to its shareholders?
Yes, Astrazeneca (AZN) offers dividends to its shareholders, with a dividend yield of 2.23%. This dividend yield represents Astrazeneca's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Astrazeneca in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of Astrazeneca?
Some of the similar stocks of Astrazeneca are Johnson & Johnson, Eli Lilly and Company, Pfizer, AbbVie, and TherapeuticsMD.
.